Organisation paid for research Program year 2025 Source: CMS Open Payments

Millennium Clinical Research Inc

Neither a doctor nor a teaching hospital

Research payments

$286,315

41 payments

Through program year 2025, Millennium Clinical Research Inc is reported as receiving $286,315 in research payments, across 41 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $12,490 2
2024 Research $11,691 9
2023 Research $79,224 12
2022 Research $70,615 7
2021 Research $14,711 2
2020 Research $404 2
2019 Research $97,181 7

Breakdown

Who paid Research payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $135,358 16 payments
  2. AstraZeneca Pharmaceuticals LP $82,821 2 payments
  3. Pfizer Inc. $43,471 7 payments
  4. Shire North American Group Inc $13,244 4 payments
  5. Galderma Laboratories, L.P. $9,691 8 payments
  6. Akebia Therapeutics Inc $1,537 3 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $194 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 1/2, Randomized, Observer-Blinded, Multi-Country Study to Eval $135,358 16 payments
  2. A Phase 3 Multicenter Randomised Open Label Active-Controlled Study of the Safety and Efficacy of Roxadustat in the Treatment of Anemia in Dialysis Patients $78,297 1 payment
  3. A Phase 12 Randomized Study to Evaluate the Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Influenza in Healthy Individuals $31,171 5 payments
  4. A Phase 3 Randomized Doubleblind 52Week Placebocontrolled Multicenter Study Investigating the Efficacy Safety and Tolerability of Ritlecitinib in Adult and Adolescent Participants With Non Segmental Vitiligo $12,300 2 payments
  5. A Double-Blind, Placebo-Controlled, Randomized Study to Assess the Durability of Effect and Safety of Nemolizumab for 24 Weeks in Subjects With Prurigo Nodularis $9,691 8 payments
  6. A Phase 3, Multi-Center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of Shp640 Pvp-Iodine 0.6 and Dexamethasone 0.1 Ophthalmic Suspension Compared to Pvp-Iodine and Placebo in the Treatment of Adenoviral Conjunctivitis $7,244 3 payments
  7. A Phase 3, Multi-Center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of Shp640 Pvp-Iodine 0.6 and Dexamethasone 0.1 Ophthalmic Suspension Compared to Placebo in the Treatment of Bacterial Conjunctivitis $6,000 1 payment
  8. A Phase 3 Randomized Double Blind Placebo Controlled Study Evaluating the Safety and Efficacy of Roxadustat AZD9941 for the Treatment of Anemia in Chronic Kidney Disease Patients not on Dialysis $4,524 1 payment
  9. Akb-6548-Ci-0015 $1,116 1 payment
  10. Akb-6548-Ci-0014 $211 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record